From discovery to regulatory approval: a brief history of afamelanotide (Part 1)

What does it take to get a new drug approved? Afamelanotide, CLINUVEL’s core technology, was first developed in the 1980s to protect against skin cancer. Today, the drug is approved to prevent phototoxicity in erythropoietic protoporphyria (EPP) patients. In the first of a two part series, hear directly from Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, who led the much of the development and regulatory work. He recounts the challenges and triumphs of navigating the process from a promising discovery to a regulatory success for rare disease patients.